GENNIO
Gennio is a Spanish social search engine based on leading collective intelligence.
GENNIO
Industry:
Developer Tools Search Engine
Founded:
2005-04-09
Address:
Madrid, Madrid, Spain
Country:
Spain
Website Url:
http://www.gennio.com
Total Employee:
11+
Status:
Active
Contact:
91 838 86 50
Email Addresses:
[email protected]
Total Funding:
600 K USD
Technology used in webpage:
SPF SEDO DNS
Similar Organizations
Indeed
Indeed is an employment-related metasearch engine for job listings.
SEER Interactive
SEER Interactive is an online marketing agency that helps clients with SEO ranking and analytics.
More informations about "Gennio"
Team Archive - Gennao Bio
Gennao Bio Debuts Preclinical Data for First-in-Class Antibody-Drug Conjugate from Gene Monoclonal Antibody Platform (GMAB ADC) ... Mr. Campbell joined Amicus in 2006 and led the global organization responsible for the …See details»
Gennao Bio - Crunchbase Company Profile & Funding
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that …See details»
Gennao Bio Expands Leadership Team with Two Key Appointments
Jan 6, 2022 Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) …See details»
Gennao Bio - LinkedIn
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform …See details»
Gennao Bio - Drug pipelines, Patents, Clinical trials - Synapse
Explore Gennao Bio with its drug pipeline, therapeutic area, technology platform, 5 news, Disease Domain:Neoplasms, Technology Platform:Antibody oligonucleotide conjugates, Monoclonal …See details»
Gennao Bio - Contacts, Employees, Board Members, Advisors
Organization. Gennao Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 7. Number of Board …See details»
Gennao Bio Strengthens Board of Directors with Appointments of …
HOPEWELL, N.J., March 17, 2022 — Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the …See details»
Gennao Bio Appoints Chris Duke as Chief Operating Officer and …
Jul 13, 2021 “Chris has been a key advisor to Gennao for the last 12 months and played a critical role in launching the company,” said Stephen Squinto, Ph.D., chief executive officer …See details»
Gennao Bio - VentureRadar
" Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform …See details»
Gennao Bio - Funding, Financials, Valuation & Investors
Gennao Bio is a genetic medicines company that develops targeted nucleic acid therapeutics to cure muscle diseases. Search Crunchbase. Start Free Trial . ... How much funding has this …See details»
Gennao Company Profile 2025: Valuation, Funding & Investors
Gennao General Information Description. Developer of targeted nucleic acid therapeutics intended to cure muscle diseases. The company uses gene monoclonal antibody (GMAB) …See details»
Gennao Bio - Overview, News & Similar companies | ZoomInfo.com
Jan 6, 2022 Gennao Bio Announces Upcoming Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 HOPEWELL, N.J.--(BUSINESS WIRE)- …See details»
Gennao Bio Closes $40 Million Series A Financing to Develop …
May 10, 2021 Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. Investor …See details»
Bradley Campbell - Gennao Bio
Bradley Campbell is president and chief executive officer of Amicus Therapeutics and is also a member of its Board of Directors. Mr. Campbell joined Amicus in 2006 and led the global …See details»
Gennao Bio (Gennao Bio) - 药物管线_专利_临床试验_投融营收_最 …
了解Gennao Bio (Gennao Bio)公司的药物管线，治疗领域，技术平台，以及它的11篇新闻，疾病领域:肿瘤，技术平台:抗体核酸偶联药物，单克隆抗体，药物:GMAB-D31N/3pRNA …See details»
Highlighting 25 Top Cancer Gene Therapy Companies - Inven
The organization is comprised of experienced leaders in clinical oncology who are dedicated to positively impacting the lives of people with cancer. 20. Versant Ventures. Website: …See details»
3E10-D31N - Drug Targets, Indications, Patents - Synapse
Nov 21, 2024 ~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a cell penetrating antibody, to non-covalently bind to and …See details»
前沿专利 | Gennao Bio — 强强联合的抗肿瘤AOC医药新闻-ByDrug …
Aug 14, 2024 相较于仅通过对3E10进行抗体工程性改造，Gennao Bio采用了更广阔的思路，即核酸递送。 与ADC中的毒素payload不同，基于抗体的核酸递送的一个主要担忧就是核酸若由 …See details»
Bruce Turner, M.D., Ph.D. - Gennao Bio
He also spent five years at Hoffman-La Roche in various positions and helped lead the re-organization of the cardiovascular franchise among other responsibilities. Prior to joining …See details»
How organizations can harness the power of GenAI for good
4 days ago We’re also working with a global automotive company in the field of mobility and AI-enabled telecommunications to help prevent traffic accidents. The company is making safety …See details»